KemPharm, Inc. (NASDAQ:KMPH) Sees Significant Growth in Short Interest
KemPharm, Inc. (NASDAQ:KMPH) Sees Significant Growth in Short Interest
KemPharm, Inc. (NASDAQ:KMPH – Get Rating) was the target of a significant increase in short interest during the month of December. As of December 30th, there was short interest totalling 1,630,000 shares, an increase of 5.2% from the December 15th total of 1,550,000 shares. Currently, 5.2% of the company's stock are sold short. Based on an average trading volume of 208,300 shares, the days-to-cover ratio is presently 7.8 days.
肯德基製藥公司(納斯達克:Kmph-Get Rating)是空頭股數12月份大幅增長的目標。截至12月30日,空頭股數共有163萬股,比12月15日的155萬股增加了5.2%。目前,該公司5.2%的股票被賣空。以平均成交量208,300股計算,目前天數與回補比率為7.8天。
Insider Transactions at KemPharm
肯德基製藥公司的內幕交易
In other news, CEO Richard W. Pascoe acquired 9,500 shares of the stock in a transaction that occurred on Friday, January 13th. The stock was purchased at an average cost of $5.44 per share, with a total value of $51,680.00. Following the completion of the acquisition, the chief executive officer now directly owns 19,973 shares in the company, valued at $108,653.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.10% of the company's stock.
在其他新聞方面,首席執行官理查德·W·帕斯科在1月13日星期五的一筆交易中收購了9,500股該公司股票。這隻股票是以每股5.44美元的平均價格購買的,總價值為51,680.00美元。收購完成後,首席執行官現在直接擁有該公司19,973股,價值108,653.12美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。企業內部人士持有該公司1.10%的股份。
Hedge Funds Weigh In On KemPharm
對衝基金對KemPharm的看法
Several institutional investors and hedge funds have recently bought and sold shares of KMPH. Laurion Capital Management LP acquired a new stake in shares of KemPharm during the 2nd quarter valued at about $2,597,000. Janney Montgomery Scott LLC lifted its holdings in shares of KemPharm by 36.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 479,220 shares of the specialty pharmaceutical company's stock valued at $2,166,000 after buying an additional 129,100 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of KemPharm during the 1st quarter valued at about $114,000. JPMorgan Chase & Co. lifted its holdings in shares of KemPharm by 28.3% during the 1st quarter. JPMorgan Chase & Co. now owns 18,095 shares of the specialty pharmaceutical company's stock valued at $91,000 after buying an additional 3,990 shares during the last quarter. Finally, Kingsview Wealth Management LLC acquired a new stake in shares of KemPharm during the 2nd quarter valued at about $54,000. Hedge funds and other institutional investors own 19.39% of the company's stock.
幾家機構投資者和對衝基金最近買賣了KMPH的股票。Laurion Capital Management LP在第二季度收購了肯帕姆公司的新股份,價值約259.7萬美元。Janney Montgomery Scott LLC在第二季度增持了36.9%的KemPharm股票。Janney Montgomery Scott LLC現在擁有479,220股這家專業製藥公司的股票,價值2,166,000美元,在上個季度又購買了129,100股。工程師門經理LP在第一季度收購了價值約11.4萬美元的KemPharm股票。摩根大通在第一季度增持了28.3%的肯德基股票。摩根大通(JPMorgan Chase&Co.)現在持有這家專業製藥公司18,095股股票,價值91,000美元,上個季度又購買了3,990股。最後,Kingsview Wealth Management LLC在第二季度收購了價值約5.4萬美元的肯德基新股。對衝基金和其他機構投資者持有該公司19.39%的股份。
KemPharm Trading Down 10.5 %
KemPharm股價下跌10.5%
KemPharm (NASDAQ:KMPH – Get Rating) last released its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). KemPharm had a negative return on equity of 16.12% and a negative net margin of 328.56%. The company had revenue of $2.87 million for the quarter, compared to analysts' expectations of $2.97 million. On average, analysts expect that KemPharm will post -0.65 earnings per share for the current fiscal year.
納斯達克(Kmph-Get Rating)上一次發佈財報是在11月9日星期三。這家專業製藥公司公佈了本季度每股收益(0.19美元),符合普遍預期的(0.19美元)。凱姆帕姆的淨資產回報率為負16.12%,淨利潤率為負328.56%。該公司當季營收為287萬美元,高於分析師預期的297萬美元。分析師平均預計,KemPharm本財年的每股收益將為0.65美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several equities analysts have recently issued reports on the company. StockNews.com upgraded KemPharm from a "sell" rating to a "hold" rating in a research report on Saturday, November 19th. Cantor Fitzgerald assumed coverage on KemPharm in a report on Thursday, November 17th. They set an "overweight" rating and a $20.00 target price on the stock. Finally, Canaccord Genuity Group lowered their target price on KemPharm from $20.00 to $19.00 in a report on Thursday, November 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.25.
幾位股票分析師最近發佈了關於該公司的報告。在11月19日星期六發布的一份研究報告中,StockNews.com將KemPharm的評級從賣出上調至持有。坎託·菲茨傑拉德在11月17日星期四的一份報告中對肯德基製藥公司進行了報道。他們為該股設定了“增持”評級和20.00美元的目標價。最後,在11月10日星期四的一份報告中,Canaccel Genuity Group將KemPharm的目標價從20.00美元下調至19.00美元。一位股票研究分析師對該股的評級為持有,四位分析師對該公司的評級為買入。根據MarketBeat.com的數據,該股目前的平均評級為“中等買入”,平均目標價為17.25美元。
KemPharm Company Profile
肯德基製藥公司簡介
(Get Rating)
(獲取評級)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
凱姆製藥公司是一家臨牀階段的專業製藥公司,致力於專利前體藥物的發現和開發。它專注於通過其名為配體激活療法的平臺技術來治療嚴重的疾病,如注意力缺陷多動障礙、疼痛和其他中樞神經系統疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on KemPharm (KMPH)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
- 免費獲取StockNews.com關於KemPharm的研究報告(KMPH)
- EVGO股票充值,駕馭電動汽車普及浪潮
- 高通從分析師那裏得到了提振,但現在是收購的時候了嗎?
- 高收益、高價值的Verizon陷入谷底
- 你應該用這隻反向ETF做空納斯達克100指數嗎?
- 科蒂股票能否在2023年出現上行
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.
接受KemPharm日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對肯德基製藥及相關公司評級的每日簡要摘要。